Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00540982 · ClinicalTrials.gov registry record · Phase 1
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00540982 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 47 participants.
The verdict
NCT00540982, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This pilot trial is studying the side effects and best dose of vinorelbine in treating patients with advanced solid tumors that have not responded to treatment and liver dysfunction.
Interventions
- OTHER high performance liquid chromatography
- DRUG lidocaine
- DRUG vinorelbine ditartrate
- DRUG indocyanine green
- OTHER intracellular fluorescence polarization analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 1997-02-20 |
| Est. Completion | 2010-05-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00540982
The ClinicalTrials.gov registry entry for NCT00540982 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which high performance liquid chromatography is the first listed.
NCT00540982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00540982 about?
NCT00540982 is a clinical study titled "Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction". RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This pilot trial is studying the side effects and best dose of vinorelbine in treating patients with advanced...
What is the current status of trial NCT00540982?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 1997-02-20. Estimated completion is 2010-05-20.
What interventions are being tested in trial NCT00540982?
The interventions under investigation include: high performance liquid chromatography (OTHER), lidocaine (DRUG), vinorelbine ditartrate (DRUG), indocyanine green (DRUG), intracellular fluorescence polarization analysis (OTHER).
Who is sponsoring clinical trial NCT00540982?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.